Probiotic Soy Product Supplemented with Isoflavones Improves the Lipid Profile of Moderately Hypercholesterolemic Men: A Randomized Controlled Trial

Overview

Journal Nutrients

Date 2016 Jan 23

PMID 26797632

Citations 22

Authors

Daniela Cardoso Umbelino Cavallini

Marla Simone Jovenasso Manzoni

Raquel Bedani

Mariana Nougalli Roselino

Larissa Sbaglia Celiberto

Regina Celia Vendramini

Graciela Font de Valdez

Dulcineia Saes Parra Abdalla

Roseli Aparecida Pinto

Daniella Rosetto

Sandro Roberto Valentini

Elizeu Antonio Rossi

Affiliations

Soon will be listed here.

Abstract

Background: Cardiovascular disease is the leading cause of worldwide morbidity and mortality. Several studies have demonstrated that specific probiotics affect the host's metabolism and may influence the cardiovascular disease risk.

Objectives: The aim of this study was to investigate the influence of an isoflavone-supplemented soy product fermented with Enterococcus faecium CRL 183 and Lactobacillus helveticus 416 on cardiovascular risk markers in moderately hypercholesterolemic subjects.

Design: Randomized placebo-controlled double-blind trial Setting: São Paulo State University in Araraquara, SP, Brazil.

Participants: 49 male healthy men with total cholesterol (TC) >5.17 mmol/L and <6.21 mmol/L Intervention: The volunteers have consumed 200 mL of the probiotic soy product (group SP-10(10) CFU/day), isoflavone-supplemented probiotic soy product (group ISP-probiotic plus 50 mg of total isoflavones/100 g) or unfermented soy product (group USP-placebo) for 42 days in a randomized, double-blind study.

Main Outcome Measures: Lipid profile and additional cardiovascular biomarkers were analyzed on days 0, 30 and 42. Urine samples (24 h) were collected at baseline and at the end of the experiment so as to determine the isoflavones profile.

Results: After 42 days, the ISP consumption led to improved total cholesterol, non-HDL-C (LDL + IDL + VLDL cholesterol fractions) and electronegative LDL concentrations (reduction of 13.8%, 14.7% and 24.2%, respectively, p < 0.05). The ISP and SP have prevented the reduction of HDL-C level after 42 days. The C-reactive protein and fibrinogen levels were not improved. The equol production by the ISP group subjects was inversely correlated with electronegative LDL concentration.

Conclusions: The results suggest that a regular consumption of this probiotic soy product, supplemented with isoflavones, could contribute to reducing the risk of cardiovascular diseases in moderately hypercholesterolemic men, through the an improvement in lipid profile and antioxidant properties.

Citing Articles

Polyphenol-Derived Microbiota Metabolites and Cardiovascular Health: A Concise Review of Human Studies.

Pinaffi-Langley A, Tarantini S, Hord N, Yabluchanskiy A Antioxidants (Basel). 2025; 13(12.

PMID: 39765880 PMC: 11673714. DOI: 10.3390/antiox13121552.

Health Benefits of Prebiotics, Probiotics, Synbiotics, and Postbiotics.

Al-Habsi N, Al-Khalili M, Haque S, Elias M, Olqi N, Al Uraimi T Nutrients. 2024; 16(22).

PMID: 39599742 PMC: 11597603. DOI: 10.3390/nu16223955.

The effect of synbiotic supplementation on plasma levels of advanced glycation end products and cardiovascular risk factors in hemodialysis patients: A double-blind clinical trial.

Azamian Y, Abdollahzad H, Rezaeian S, Rouhani M, Fatehi M Food Sci Nutr. 2024; 12(9):6864-6872.

PMID: 39554367 PMC: 11561817. DOI: 10.1002/fsn3.4338.

The potential preventive effect of probiotics, prebiotics, and synbiotics on cardiovascular risk factors through modulation of gut microbiota: A review.

Ghanbari F, Hasani S, Aghili Z, Asgary S Food Sci Nutr. 2024; 12(7):4569-4580.

PMID: 39055176 PMC: 11266939. DOI: 10.1002/fsn3.4142.

Urinary Equol and Equol-Predicting Microbial Species Are Favorably Associated With Cardiometabolic Risk Markers in Chinese Adults.

Liang S, Zhang H, Mo Y, Li Y, Zhang X, Cao H J Am Heart Assoc. 2024; 13(13):e034126.

PMID: 38934874 PMC: 11255694. DOI: 10.1161/JAHA.123.034126.

References

FRIEDEWALD W, Levy R, Fredrickson D . Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18(6):499-502. View

Anthony M, Clarkson T, Hughes Jr C, Morgan T, Burke G . Soybean isoflavones improve cardiovascular risk factors without affecting the reproductive system of peripubertal rhesus monkeys. J Nutr. 1996; 126(1):43-50. DOI: 10.1093/jn/126.1.43. View

Kekkonen R, Sysi-Aho M, Seppanen-Laakso T, Julkunen I, Vapaatalo H, Oresic M . Effect of probiotic Lactobacillus rhamnosus GG intervention on global serum lipidomic profiles in healthy adults. World J Gastroenterol. 2008; 14(20):3188-94. PMC: 2712851. DOI: 10.3748/wjg.14.3188. View

Akaza H, Miyanaga N, Takashima N, Naito S, Hirao Y, Tsukamoto T . Comparisons of percent equol producers between prostate cancer patients and controls: case-controlled studies of isoflavones in Japanese, Korean and American residents. Jpn J Clin Oncol. 2004; 34(2):86-9. DOI: 10.1093/jjco/hyh015. View

Inoue T, Uchida T, Kamishirado H, Takayanagi K, Morooka S . Antibody against oxidized low density lipoprotein may predict progression or regression of atherosclerotic coronary artery disease. J Am Coll Cardiol. 2001; 37(7):1871-6. DOI: 10.1016/s0735-1097(01)01228-1. View

Wong J, Kendall C, Marchie A, Liu Z, Vidgen E, Holmes C . Equol status and blood lipid profile in hyperlipidemia after consumption of diets containing soy foods. Am J Clin Nutr. 2012; 95(3):564-71. DOI: 10.3945/ajcn.111.017418. View

Sacks F, Lichtenstein A, Van Horn L, Harris W, Kris-Etherton P, Winston M . Soy protein, isoflavones, and cardiovascular health: an American Heart Association Science Advisory for professionals from the Nutrition Committee. Circulation. 2006; 113(7):1034-44. DOI: 10.1161/CIRCULATIONAHA.106.171052. View

Setchell K, Cole S . Method of defining equol-producer status and its frequency among vegetarians. J Nutr. 2006; 136(8):2188-93. DOI: 10.1093/jn/136.8.2188. View

Wierzbicki A, Hardman T, Viljoen A . New lipid-lowering drugs: an update. Int J Clin Pract. 2012; 66(3):270-80. DOI: 10.1111/j.1742-1241.2011.02867.x. View

10.

Chen D, Yang Z, Chen X, Huang Y, Yin B, Guo F . The effect of Lactobacillus rhamnosus hsryfm 1301 on the intestinal microbiota of a hyperlipidemic rat model. BMC Complement Altern Med. 2014; 14:386. PMC: 4197344. DOI: 10.1186/1472-6882-14-386. View

11.

Mendelsohn M, Karas R . The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999; 340(23):1801-11. DOI: 10.1056/NEJM199906103402306. View

12.

Toshima S, Hasegawa A, Kurabayashi M, Itabe H, Takano T, Sugano J . Circulating oxidized low density lipoprotein levels. A biochemical risk marker for coronary heart disease. Arterioscler Thromb Vasc Biol. 2000; 20(10):2243-7. DOI: 10.1161/01.atv.20.10.2243. View

13.

Karvonen J, Paivansalo M, Kesaniemi Y, Horkko S . Immunoglobulin M type of autoantibodies to oxidized low-density lipoprotein has an inverse relation to carotid artery atherosclerosis. Circulation. 2003; 108(17):2107-12. DOI: 10.1161/01.CIR.0000092891.55157.A7. View

14.

Rossi E, Vendramini R, Carlos I, Ueiji I, Squinzari M, Silva Junior S . Effects of a novel fermented soy product on the serum lipids of hypercholesterolemic rabbits. Arq Bras Cardiol. 2000; 74(3):209-16. DOI: 10.1590/s0066-782x2000000300003. View

15.

Lobo J, Mafra D, Elias Farage N, Faulin T, Saes Parra Abdalla D, de Nobrega A . Increased electronegative LDL and decreased antibodies against electronegative LDL levels correlate with inflammatory markers and adhesion molecules in hemodialysed patients. Clin Chim Acta. 2011; 412(19-20):1788-92. DOI: 10.1016/j.cca.2011.05.034. View

16.

Rossi E, Vendramini R, Carlos I, de Oliveira M, de Valdez G . [Effect of a new fermented soy milk product on serum lipid levels in normocholesterolemic adult men]. Arch Latinoam Nutr. 2003; 53(1):47-51. View

17.

Bedani R, Pauly-Silveira N, Cano V, Valentini S, de Rossi G, Valdez E . Effect of ingestion of soy yogurt on intestinal parameters of rats fed on a beef-based animal diet. Braz J Microbiol. 2013; 42(3):1238-47. PMC: 3768778. DOI: 10.1590/S1517-838220110003000050. View

18.

Zhao J, Yang H . [Progress in the effect of probiotics on cholesterol and its mechanism]. Wei Sheng Wu Xue Bao. 2005; 45(2):315-9. View

19.

Faulin T, de Sena-Evangelista K, Pacheco D, Augusto E, Saes Parra Abdalla D . Development of immunoassays for anti-electronegative LDL autoantibodies and immune complexes. Clin Chim Acta. 2011; 413(1-2):291-7. DOI: 10.1016/j.cca.2011.10.004. View

20.

Simons L, Amansec S, Conway P . Effect of Lactobacillus fermentum on serum lipids in subjects with elevated serum cholesterol. Nutr Metab Cardiovasc Dis. 2006; 16(8):531-5. DOI: 10.1016/j.numecd.2005.10.009. View